A flurry of developments in late January 2025 has caused quite a buzz in the AI world. On January 20, DeepSeek released a new open-source AI model called R1 and an accompanying research paper....more
Integrating AI tools into drug discovery introduces a mix of opportunities and challenges for startups and large pharmaceutical companies. These challenges often center on intellectual property (IP) risks, licensing...more
1/15/2025
/ Acquisitions ,
Artificial Intelligence ,
Documentation ,
Due Diligence ,
Innovation ,
Intellectual Property Protection ,
IP License ,
Life Sciences ,
Mergers ,
Patents ,
Pharmaceutical Industry ,
Risk Management ,
Startups
AI is poised to revolutionize drug discovery, but uncertainty in developing protectable IP in this emerging field creates a host of potential risks for companies innovating in this space. Further complicating things: not all...more
The scientific benefits and legal risks of AI-driven drug discovery are consequential. But recent IP law decisions allude to a general concept that IP rights will not be awarded if AI completely or significantly replaces...more
Open models play a crucial role in fostering a diverse and innovative AI ecosystem. But their irrevocable accessibility also presents challenges for preventing downstream misuse—and that has caught the government’s attention....more
9/6/2024
/ Artificial Intelligence ,
Best Practices ,
Biden Administration ,
Executive Orders ,
Governor Newsom ,
NIST ,
NTIA ,
Pending Legislation ,
Proposed Legislation ,
Public Comment ,
Regulatory Agenda ,
Regulatory Oversight ,
U.S. Commerce Department
AI is shaving years off the drug-discovery process. But it’s not just leaving other research modalities in the dust—the law itself is struggling to keep up, especially when it comes to patenting AI-aided drug discovery....more
6/14/2024
/ Artificial Intelligence ,
Inventors ,
Life Sciences ,
Machine Learning ,
Patents ,
Pharmaceutical Industry ,
Research and Development ,
Risk Assessment ,
Risk Management ,
Startups ,
Strategic Planning ,
USPTO
AI is vaulting drug discovery forward leaps and bounds—and now regulators are beginning to catch up, with the United States Patent and Trademark Office recently issuing new guidelines on the patentability of AI-assisted...more